What can be acheived with triple combination therapy Phase I trial for metastatic melanoma

What can be acheived with triple combination therapy Phase I trial for metastatic melanoma

VJOncology

3 years
791 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jeffrey Weber, MD, PhD from the NYU Langone Medical Center, New York, NY discusses what he hopes to achieve with an upcoming Phase I, triple combination therapy trial in metastatic melanoma while at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Prof. Weber begins by explaining how at the beginning of a treatment regimen with high response rate and outstanding survival, tolerability and toxicity are assessed in order to determine if a third drug, like a histone deacetylator (HDAC) inhibitor can be added to the backbone of ipilimumab and nivolumab. Correlative studies carried out alongside can help to understand which genes are altered in their expression when the HDAC inhibitor is given in combination with ipilimumab and nivolumab. In addition peripheral blood parameters will be monitored at baseline to see if they are predictive of patient outcome. Ultimately, Prof. Weber says that if the triple combinations are well tolerated, a randomised Phase II trial should be considered for the triple combination compared to the double combination of ipilimumab and nivolumab.
Up Next Autoplay
Zomas Question 2
Zomas Question 2
Category: Chronic Myelogenous Leukemia
0 Views
admin 4 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
3 Views
ash 6 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 7 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
admin 7 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 8 hours
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 9 hours
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC
Category: Chronic Lymphocytic Leukemia
0 Views
ash 9 hours
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
4 Views
ash 22 hours
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
6 Views
ash 23 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
6 Views
ash 1 day